Robust Mouse Rejuvenation:
Breaking the Ceiling of Longevity Research
For decades, the field of biogerontology has largely focused on a single strategy: manipulating metabolism to slow down the rate at which we age. While approaches like caloric restriction have produced fascinating results in short-lived organisms like worms and flies, they have shown clear limits in mammals. Slowing the accumulation of damage does not remove the damage that is already there. It merely delays (not prevents) the onset of disease, particularly when applied late in life.
At LEV Foundation, we are pursuing a distinct alternative: maintenance through damage repair.
Aging is the accumulation of molecular and cellular damage as a side-effect of normal metabolism. While our body is set up to tolerate a certain amount of such damage, the accumulation eventually breaches a threshold of resilience, leading to the cascade of chronic diseases we associate with aging and eventual death. For a long time, a certain pessimism has permeated the scientific community: the belief that aging is simply too complex to be meaningfully postponed within our lifetimes. We broadly agree with this assessment, provided one is trying to retune human metabolism. Our metabolic network is so inextricably intertwined and still so poorly understood that safely manipulating it offers little prospect of success.
However, when we shift our focus from the messy processes that create damage to the structural damage itself, the problem becomes much more tractable. All age-related damage can be classified into a manageable number of categories.¹ Just as regular maintenance keeps a car running indefinitely, we can restore function by periodically repairing this damage, without needing to tweak the body’s incredibly complex biology.
This still leaves an important precondition. Since there are different types of damage, a single therapeutic intervention is insufficient. Attacking one aspect of aging while ignoring the others yields only marginal gains, because the neglected types of damage will simply prove fatal on the same timeline. To achieve meaningful rejuvenation, we must move from isolation to synergy.
This necessity is the foundation of the Robust Mouse Rejuvenation (RMR) programme.² We define RMR as a specific engineering benchmark: a multi-component intervention that increases both mean and maximum lifespan in mice by at least 12 months. This must be achieved in a mouse strain with a well-documented mean lifespan of at least 30 months, with treatment initiating only at the advanced age of 18 months.
To hit this target, the RMR programme consists of large-scale studies designed to determine how leading-edge interventions behave when deployed together. Are the effects additive, synergistic, or perhaps antagonistic? RMR1 served as a first test, operating at an unprecedented scale with 1000 middle-aged mice divided into 10 subgroups per sex. This granular design allowed us to map the complex web of interactions. We selected four interventions that had individually shown promise in extending mouse lifespan: rapamycin,³ senolytics,⁴ telomerase gene therapy,⁵ and hematopoietic stem cell transplantation. By administering these simultaneously, we sought to establish whether their combined impact could finally break through the lifespan ceiling that no single intervention has ever managed to overcome.
The ultimate motivation for RMR, however, extends far beyond the laboratory. Society is currently trapped in a pro-aging trance: the fatalistic belief that aging is immutable and therefore desirable. As outlined by Terror Management Theory, humans subconsciously rationalise inevitable mortality to avoid psychological paralysis.⁶ ⁷ Logic alone cannot shift such entrenched views. It takes the shock of seeing the impossible become real to change minds.
Much like the release of ChatGPT instantly shifted public perception of what is possible in AI, success in RMR would provide that demonstration for longevity: a definitive proof of concept that aging is malleable even in late life. A result of this magnitude would make it impossible for experts to dismiss the feasibility of human rejuvenation. This scientific validation is the missing link required to engage global media and ultimately compel policymakers to allocate the resources necessary for human translation. RMR1 is the first step in generating the hard data needed to trigger this cascade.
Study Design and Methods
RMR1 was a logistics operation of significant complexity, conducted at the facilities of Ichor Life Sciences in Syracuse, New York. To test the hypothesis of synergistic damage repair, we utilised 1000 C57BL/6J mice. Treatment began at approximately 19 months of age, a biological timepoint roughly equivalent to a 60-year-old human, where the first signs of age-related mortality are already becoming apparent.
The mice were divided into 10 treatment groups per sex, staggered across four cohorts to manage the intensive labour required (no automated tracking or smart cages were used). We tested four specific interventions, chosen for their distinct mechanisms of action:
Rapamycin: An mTOR inhibitor (42ppm) delivered via enteric-coated chow to ensure consistent dosing without injection stress.
Senolytics: Galactose-conjugated Navitoclax (Gal-Nav), designed to target senescent cells, delivered initially via injection but switched to oral gavage due to solubility constraints.
Telomerase gene therapy (mTERT): Delivered via intranasal AAV virus to extend telomeres while minimising invasive procedures.
Hematopoietic stem cell transplantation (HSCT): Introduction of stem cells from young donors following a chemical mobilisation regimen (using G-CSF and AMD3100).
Uniquely, our schedule for tissue collection (culling) was determined not by chronological age, but by group-specific survival rates (e.g., when 20% of a group had died). This design ensured that biological comparisons remained valid even as the aging trajectories of the groups diverged.
Adapting to reality: key operational learnings
A study of this magnitude is a stress test for protocols. Early in the study, we faced a critical formulation challenge: the vehicle required for the injectable senolytic proved unstable and toxic (causing peritonitis) in pilot tests. In an engineering pivot, we switched the delivery method to oral gavage to ensure safety. Furthermore, to mitigate stress on the animals, we introduced a two-week recovery interval between the stem cell mobilisation and the senolytic treatment.
Crucially, to validate that the process of treatment was not distorting the readout, we utilised both “mock” controls (receiving sham injections/vehicles) and “naive” controls (no handling). This rigorous control structure allowed us to separate the biological effect of the therapy from the physiological stress of the delivery method.
Results: a “qualified win” for synergy
With the death of the final mouse on February 12, 2025, we can share the definitive lifespan outcomes (the complete survival curves for all cohorts are available in the Appendix at the end of this article).
The overarching conclusion is a “qualified win”. RMR1 has successfully demonstrated that combining damage-repair interventions with metabolic modulation (rapamycin) yields additive benefits. Specifically, we observed a distinct rectangularisation of the survival curve. This means we significantly increased mean lifespan by ensuring more mice survived into late life. However, we must be clear about the limits of this result. We did not observe a radical extension of maximum lifespan (the age of the oldest survivors). While the all-four combination group outperformed both the naive and mock controls, the “robust” goal of shifting the entire mortality window remains the target for future iterations.
Sex dimorphism and the dominance of rapamycin
The data reveals a stark contrast between sexes, reinforcing the complexity of mammalian aging.
Females: The results were dominated by rapamycin. The group receiving rapamycin-only performed nearly as well as the all-four combination group, strongly driving mean lifespan extension. However, a critical insight emerged from the all-but-rapamycin group (receiving only damage repair). These mice tracked with the top performers for the first year but then saw survival rates drop precipitously to match the controls.
The learning: This abrupt reversal suggests that damage repair works, but a single administration at 19 months is insufficient. The damage re-accumulates. Future protocols (RMR2) must likely incorporate repeated dosing for interventions like senolytics and gene therapy.
Figure 1: The drop-off effect in female cohorts (None vs. Rapamycin vs. No Rapamycin vs. All).
Males: Here, the synergy hypothesis was more clearly validated. While rapamycin alone provided benefit, it was outperformed by the all-four combination across the majority of the survival curve. Interestingly, damage-repair interventions that appeared weak or even detrimental in isolation showed their true value when combined with rapamycin. This suggests that rapamycin may provide a necessary metabolic stability that allows the mice to tolerate and benefit from aggressive damage-repair therapies.
Figure 2: Synergistic lifespan extension in male cohorts (None vs. Rapamycin vs. All).
Limitations and delivery constraints
Transparency is vital to the scientific process. We observed that the Gal-Nav senolytic, when administered alone via oral gavage, did not produce a statistically significant lifespan benefit. Based on our preliminary analysis, this is likely due to the instability of the galactose conjugation in the digestive tract. If the molecule loses its targeting moiety in the gut, it loses its efficacy as a prodrug. Tellingly, we observed no platelet toxicity, a known side effect of systemic Navitoclax, which suggests the drug was either neutralised or significantly underdosed via this route.
Additionally, the HSCT process presented a critical trade-off. While effective, the mobilisation procedure was physically stressful, and the logistics of harvesting cells from young donors proved difficult to scale ethically and practically. These factors have directly informed our shift to mesenchymal stem cells (MSCs) for RMR2.
The hidden data: a call to action
Survival curves tell us when the mice died, but they do not reveal how they lived. To understand the true quality of the lifespan extension, we are currently untangling a massive dataset of functional metrics collected throughout the study. This includes longitudinal measurements of grip strength, rotarod performance, open field activity, glucose tolerance, clinical chemistry profiles, and memory retention tests, alongside hearing assessments and body condition scoring.
However, the most critical chapter of this story remains frozen in our biobank. We possess the necessary tissue and blood samples to measure senescent cell burden, organ fibrosis, telomere length, and epigenetic age (methylation), yet the specific assays required to extract this data are currently on hold due to funding constraints.
Unlocking this information is a matter of prioritisation. A comprehensive histological analysis of all tissues would require approximately $300,000. Yet, we do not need the full sum to begin generating value. With a targeted funding injection of $50,000 to $100,000, we could immediately analyse key subsets of animals and tissues. This would allow us to investigate crucial questions, such as whether the sex-specific differences in lifespan were driven by inflammation levels or specific organ pathologies. In strictly economic terms, financing this analysis is one of the most highly leveraged philanthropic opportunities in science: it is the cheapest possible experiment required to de-risk the largest prospective biomedical industry in history.
Conclusion: paving the way for RMR2
RMR1 demonstrated that a single dose of damage repair has a limited window of efficacy. However, the male data revealed that combinatorial treatments extend this window significantly when supported by metabolic stability.
We have used these critical lessons to design RMR2. The new study replaces the single-dose approach with cyclic treatments using MSCs and an expanded panel of eight interventions. With the blueprint for this next phase complete, funding is the only remaining bottleneck.
FAQ
Does cellular reprogramming make damage repair obsolete?
Partial cellular reprogramming is a watershed development,⁸ but assuming it can fully replace damage repair is premature. The fundamental limitation is that it does not address all categories of age-related damage. Rejuvenating a cell’s epigenetic state does not automatically clear the stiff cross-links in the extracellular matrix, nor does it remove certain toxic aggregates that even young cells lack the natural enzymes to degrade. Even a perfectly rejuvenated cell will struggle to function if it remains trapped in a decaying environment. Furthermore, applying this technology safely in a whole organism still requires extensive research, given the risk of triggering cancer if the reprogramming process overshoots. That said, we do not view reprogramming as a rival paradigm. Indeed, it is one of the eight interventions planned for RMR2.Doesn’t combining many treatments risk severe side-effects?
Combining multiple experimental therapies undeniably introduces the risk of pharmacological cross-reactions. Since we must target different categories of damage simultaneously to achieve meaningful results, resolving these interactions is essential. The entire purpose of our large-scale studies is to do the unglamorous work of testing these combinations systematically in animal models, identifying exactly which therapies synergise and which conflict before they ever reach human trials.More importantly, there is a strong biological rationale for why damage-repair therapies should ultimately produce fewer side-effects than traditional geriatric medicine. Most currently available treatments attempt to alter the body’s metabolism. Because our metabolic network is so tightly interwoven, forcing a change in one pathway almost inevitably triggers unintended consequences elsewhere.
Conversely, the damage-repair approach does not attempt to force the metabolic network to operate differently. While our current protocols still rely on rapamycin to provide the metabolic stability required for the therapies to actually take effect, the drug acts merely as a facilitator. The core interventions aim to directly remove the accumulated damage. Because this damage is inherently harmful, removing it is far less likely to cause the dangerous ripple effects associated with metabolic manipulation.
Will extending a mouse’s lifespan actually translate to humans?
While a mouse ages far more rapidly than a human, the underlying mechanism is the same: the accumulation of specific, identifiable categories of cellular and molecular damage. A therapy that clears this damage in an elderly mouse will undoubtedly require substantial modification before it can safely treat a human patient. Therefore, our immediate goal is not to fast-track a specific mouse therapy into clinical trials, but rather to secure a definitive proof of concept that late-life rejuvenation is fundamentally possible in a mammal.
Demonstrating that we can take an elderly mouse and double its remaining lifespan will shatter the public perception of aging as an inescapable fate. A breakthrough of this kind will de-risk the rejuvenation paradigm, triggering a massive influx of both institutional grants and private biotech capital to fund human-specific translational research. The key insight is that the first generation of human therapies does not need to solve aging entirely. It simply needs to repair enough damage to buy people alive today the time required to benefit from subsequent, more advanced treatments (longevity escape velocity).⁹
Is this rigorous science, or just more longevity hype?
The longevity field has unfortunately seen its share of premature commercialisation. Public trust is fragile and must be earned through rigorous, transparent science. This is exactly why LEV Foundation operates as an independent non-profit. The broader biomedical landscape is heavily constrained by structural incentives. Industry is driven by venture capital, which demands rapid returns and inevitably forces companies to pursue low-hanging fruit. Conversely, traditional academia is governed by the pressure to publish frequently in prestigious journals, encouraging researchers to select safe, short-term projects. Neither environment is suited for complex, long-term synergy studies like ours.
Philanthropic funding gives us the freedom to tackle these neglected challenges. We can test unpatentable combinations and off-patent therapies that generate zero intellectual property but possess the genuine potential to advance the science of rejuvenation. This foundational phase allows subsequent biotech initiatives to develop and patent human therapeutics based on our blueprints. We also maintain radical transparency by publishing our raw survival data in real-time online, allowing anyone to track the exact progress of our cohorts as they age.
Appendix: Full Survival Curves
References
[1] de Grey AD (2002). Time to talk SENS: critiquing the immutability of human aging. Annals of the New York Academy of Sciences.
[2] Lewis CJ, de Grey AD (2024). Combining rejuvenation interventions in rodents: a milestone in biomedical gerontology whose time has come. Expert Opinion on Therapeutic Targets.
[3] Harrison DE, et al. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature.
[4] Xu M, et al. (2018). Senolytics improve physical function and increase lifespan in old age. Nature Medicine.
[5] Bernardes de Jesus B, et al. (2012). Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Molecular Medicine.
[6] Becker E (1973). The Denial of Death. Free Press.
[7] Rosenblatt A, et al. (1989). Evidence for terror management theory: I. The effects of mortality salience on reactions to those who violate or uphold cultural values. Journal of Personality and Social Psychology.
[8] Ocampo A, et al. (2016). In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. Cell.
[9] de Grey AD (2004). Escape velocity: why the prospect of extreme human life extension matters now. PLoS Biology.